Patisiran (sodium)

• UNSPSC Description:

  Patisiran sodium is a double-stranded small interfering RNA that targets a sequence within the transthyretin (TTR) messenger RNA. Patisiran sodium specifically inhibits hepatic synthesis of mutant and wild-type TTR. Patisiran sodium can be used for the research of hereditary TTR amyloidosis[1][2][3].

• Target Antigen:

  Small Interfering RNA (siRNA); Transthyretin (TTR)

• Type:

  Oligonucleotides

• Related Pathways:

  Epigenetics;Neuronal Signaling

• Field of Research:

  Neurological Disease

• Assay Protocol:

  https://www.medchemexpress.com/patisiran-sodium.html

• Purity:

  98.84

• Solubility:

  H2O : 33.33 mg/mL (ultrasonic)

• Smiles:

  [Patisiran (sodium)]

• Molecular Weight:

  13427.10 (AS: 6661.3; SS: 6765.8)

• References & Citations:

  [1]Adams D, et, al. Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis. N Engl J Med. 2018 Jul 5;379(1):11-21.|[2]Hoy SM. Patisiran: First Global Approval. Drugs. 2018 Oct;78(15):1625-1631.|[3]Kristen AV, et, al. Patisiran, an RNAi therapeutic for the treatment of hereditary transthyretin-mediated amyloidosis. Neurodegener Dis Manag. 2019 Feb;9(1):5-23.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -20°C (Powder, stored under nitrogen)

• Clinical Information:

  Launched

• CAS Number:

  1386913-72-9